Miraculins Announces Closing of Private Placement Offering
(firmenpresse) - WINNIPEG, MANITOBA -- (Marketwired) -- 12/11/14 -- Miraculins Inc. (TSX VENTURE: MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, has closed a private placement offering (the "Offering") with aggregate gross proceeds to the Company of $200,000 from the sale of 2,000,000 units ("Units") at a price of $0.10 per Unit. Each Unit is comprised of one common share of the Company (a "Share") and one Share purchase warrant (a "Warrant").
Each whole Warrant entitles the holder to purchase one Share at a price of $0.13 per Share for a period of two years from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The net proceeds of the Offering shall be used for general corporate purposes.
The closing of the Offering is subject to the final approval of the TSX Venture Exchange.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2014 - 03:58 Uhr
Sprache: Deutsch
News-ID 359017
Anzahl Zeichen: 0
contact information:
Town:
WINNIPEG, MANITOBA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Miraculins Announces Closing of Private Placement Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
Miraculins Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
